Physician profile
Robert Lugliani
NPI 1699712943
$2,908.38
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $985 · 2020: $488 · 2021: $621 · 2022: $814.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $692.84 | 2019-2022 | |
| Glaxosmithkline, LLC. | $675.78 | 2019-2022 | |
| Mylan Specialty L.P. | $406.67 | 2019-2022 | |
| Pfizer INC. | $287.75 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $208.51 | 2022 | |
| Vanda Pharmaceuticals INC. | $140.26 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $95.97 | 2019 | |
| Eisai INC. | $59.51 | 2021 | |
| Allergan, INC. | $45.50 | 2020 | |
| Gilead Sciences, INC. | $39.55 | 2022 | |
| Philips North America LLC | $38.82 | 2019-2020 | |
| Electromed, INC. | $33.08 | 2022 | |
| Baxter Healthcare | $29.63 | 2022 | |
| Nabriva Therapeutics, Plc | $23.78 | 2022 | |
| Paratek Pharmaceuticals, INC. | $22.05 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $19.15 | 2021 | |
| Lilly USA, LLC | $18.45 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.29 | 2020 | |
| Merck Sharp & Dohme LLC | $14.38 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.83 | 2021 | |
| Inogen, INC. | $12.96 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.62 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lugliani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.